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Abstract Bone morphogenetic proteins (BMPs) were discov-
ered as potent bone-inducing molecules. Their effect on
adipogenic differentiation is not well understood, both stimula-
tion and inhibition of the process have been described. We show
here that BMP-2 strongly stimulates adipogenic differentiation
of murine 3T3-L1 preadipocytes if applied together with an
agonist of peroxisome proliferator-activated receptor Q (PPARQ).
On its own, BMP-2 (500 ng/ml) did not stimulate adipogenesis as
quantified by flow cytometry with the lipophilic dye Nile Red.
However, the protein strongly potentiated adipogenesis stimu-
lated by the thiazolidinedione BRL 49653 as well as glycerol-3-
phosphate dehydrogenase activity and induction of mRNAs for
the adipogenic markers PPARQ and adipsin. We confirmed the
synergistic action of BMP-2 and BRL 49653 with primary
cultures of rat bone marrow stromal cells. Our data demonstrate
that BMP-2 can act as a potent adipogenic agent if presented
together with activators of PPARQ. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Bone morphogenetic proteins (BMPs) belong to the trans-
forming growth factor L family of growth and di¡erentiation
factors. First isolated from bone as potent inducers of ectopic
ossi¢cation [1^3], BMPs are today known to exert a variety of
functions during embryonal development and in adult organ-
isms [4,5].
The BMP family of proteins comprises more than 20 mol-
ecules. Among these, BMP-2, BMP-4, BMP-6 and BMP-7
(OP-1) have been extensively characterized as agents inducing
bone formation in vitro and in vivo [2^5].
Like osteoblasts and chondrocytes, adipocytes arise from
mesenchymal precursor cells through a di¡erentiation process
that can be recapitulated in vitro. The nuclear hormone re-
ceptor peroxisome proliferator-activated receptor Q (PPARQ)
has been shown to be a key regulator of this process [6,7] and
PPARQ activators like certain prostaglandin derivatives, lipid
messengers and the synthetic insulin-sensitizing thiazolidine-
diones are known as strong inducers of adipogenesis [8^
10].
As adipocytes and osteoblasts originate from common pre-
cursor cells [11,12] it was tempting to speculate that PPARQ
activators and BMPs would oppose each other with respect to
cell di¡erentiation, inducing adipogenic and osteogenic sig-
nals, respectively. Recent publications indeed supported this
notion. Gimble et al. reported that BMP-2 inhibits adipogenic
di¡erentiation of a bone marrow stromal cell line [13] and
Gori et al. [14], studying an immortalized human mesenchy-
mal precursor cell line, showed that BMP-2 directs cell di¡er-
entiation away from the adipogenic towards the osteogenic
pathway. However, in both series of experiments, no potent
PPARQ activators were used to induce adipogenic di¡erentia-
tion. In contrast, work from other laboratories has indicated
that BMPs can induce both osteogenesis and adipogenesis in
the murine pluripotent cell line C3H10T1/2 under speci¢c
culture conditions [15,16]. More recently Chen et al. demon-
strated that BMP-2 transmits osteogenic and adipogenic sig-
nals through di¡erent receptor subunits [17].
We have re-evaluated the adipogenic action of BMP-2 using
as experimental model the well known preadipocyte cell line
3T3-L1 as well as primary cultures of rat bone marrow stro-
mal cells. We show that BMP-2 becomes a strong inducer of
adipogenic di¡erentiation if associated with a thiazolidine-
dione activator of PPARQ. Our results provide a rationale
to explain diverging results obtained with BMP-2 as an adi-
pogenic agent. The strong synergy observed between BMP-2
and PPARQ agonists may also be relevant for our general
understanding of cell di¡erentiation processes stimulated by
both types of factors.
2. Materials and methods
2.1. Materials
If not otherwise stated, ¢ne chemicals were obtained from Sigma,
Buchs, Switzerland. BMP-2 and BRL 49653 were produced at Novar-
tis Pharma AG, Basel, Switzerland.
2.2. Cell culture
The 3T3-L1 cells were grown in MEMK/Ham’s F12 medium (1:1)
(Life Technologies, Basel, Switzerland) supplemented with 10% fetal
calf serum (Life Technologies).
Primary cultures of rat bone marrow mesenchymal cells were pre-
pared according to a published method [18]. Brie£y, bone marrow was
£ushed out of femurs and tibias of young adult female Wistar rats
using a syringe and culture medium (MEMK/Ham’s F12 as described
above). Primary cultures were established using approximately
60U106 bone marrow cells per T75 culture £ask and mesenchymal
cells were allowed to adhere to the substratum for 2 days. Hemato-
poietic cells were then eliminated by washing and medium change.
Cultures were grown to con£uence, passaged 1:4 and frozen at the
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end of passage 1. Routine experiments were carried out with cells
taken from frozen stocks and used between passages 2 and 6.
For adipogenic di¡erentiation experiments, cells were seeded at a
density of 104 cells per cm2 in either six-well plates (cyto£uorometry),
24-well plates (glycerol-3-phosphate dehydrogenase (GPDH) assay) or
10 cm culture plates (RNA extraction) and grown to con£uence for
3 to 4 days. Cultures were then treated with BRL 49653, BMP-2, 3-
isobutyl-1-methylxanthine (IBMX) or combinations thereof in full
medium supplemented with 10 mM L-glycerophosphate and 50 WM
ascorbic acid phosphate. The latter are components of osteogenic
di¡erentiation media which we included in this series of experiments
in order to have similar experimental conditions in osteogenic and
adipogenic di¡erentiation assays (to be reported elsewhere). Ascorbic
acid promotes extracellular collagen matrix formation and supports
both osteogenic and adipogenic di¡erentiation, L-glycerophosphate
constitutes a phosphate reserve supporting mineral deposition in os-
teogenic di¡erentiation assays and has no e¡ect on adipogenic di¡er-
entiation ([19] and unpublished results). Cultures were maintained
under di¡erentiating conditions for up to 2 weeks as indicated in
Section 3, with twice weekly medium change.
The presence of mature adipocytes was assessed either by Oil Red O
staining of cultures or by cyto£uorometry with Nile Red (see Section
2.4). For Oil Red O staining, cell monolayers were washed with cal-
cium- and magnesium-free phosphate-bu¡ered saline (PBS) and ¢xed
with 4% paraformaldehyde. The ¢xed cells were then covered with
3 mg/ml Oil Red O dissolved in 60% isopropanol (v/v) for 10 min,
before excess dye was washed away with H2O.
2.3. GPDH activity assay
For biochemical determination of GPDH activity we used a proto-
col adapted from Pairault and Green [20]. Brie£y, cells were washed
with PBS, covered with a solution containing 20 mM Tris, 1 mM
EDTA, 1 mM L-mercaptoethanol (BioRad, Glattbrugg, Switzerland)
and harvested in a tube maintained on ice. After passing six times
through a G20 needle to break the cells, the suspension was centri-
fuged for 3 min at 5000Ug at 4‡C. Aliquots of the supernatant were
incubated at 37‡C in 1 ml of assay solution containing 0.1 M trietha-
nolamine, 2.5 mM EDTA, 0.1 mM L-mercaptoethanol, 125 WM nic-
otinamide adenine dinucleotide, reduced form (NADH) (Roche,
Basel, Switzerland) and 200 WM dihydroxyacetonephosphate. Enzyme
activity is re£ected by the disappearance of NADH measured by
absorption at 340 nm over 10^20 min. The protein content of each
sample was analyzed in parallel using the BioRadDC Protein Assay.
Results are expressed as mU/Wg protein (1 mU = 1 nmol NADH/
min). All determinations were done in duplicate (with the exception
of the data in Table 1, experiment 1, which were single determina-
tions). Error bars indicate mean þ range. For statistical analysis of
data we used Student’s t-test as provided by Microsoft Excel (two-
tailed, two samples with equal variance).
2.4. Flow cytometry
The quanti¢cation of adipocytes in culture using the lipophilic £uo-
rescent dye Nile Red was carried out essentially as described by Gim-
ble et al. [13]. Cells were trypsinized carefully and centrifuged for
5 min at 200Ug at 4‡C. The cell pellet was resuspended and ¢xed with
4% paraformaldehyde at 4‡C. For £ow cytometry, the cells were again
sedimented as described above, resuspended in cold PBS with a ¢nal
Nile Red concentration of 1 Wg/ml and kept on ice for 30 min. The
samples were then analyzed with a FACScan1 £ow cytometer (Bec-
ton Dickinson, Basel, Switzerland). Nile Red £uorescence was meas-
ured on the FL2 emission channel through a 585 þ 21 nm band pass
¢lter, following excitation with an argon ion laser source at 488 nm.
Using a forward scatter (FSC)/side scatter representation of events, a
¢rst R1 region was de¢ned to exclude cellular debris from the analy-
sis. A selection window called R2 was then established on the FL2/
FSC blot of the R1 population as indicated in Fig. 1 in order to count
cells with high FL2 values (adipocytes). Data analysis was performed
using CellQuest1 3.1 software (Becton Dickinson). For each sample
20 000 events were collected. The results are expressed as the percent-
age of cells appearing in the R2 region.
2.5. Reverse transcription-polymerase chain reaction (RT-PCR)
RNA was extracted from cell cultures using the RNeasy Midi Kit
(Qiagen, Basel, Switzerland) following the instructions of the manu-
facturer. After DNase treatment of the samples (Promega, Basel,
Switzerland), reverse transcription was carried out using MMLV re-
verse transcriptase (Promega). Preparations of cDNA were quality-
controlled with respect to the absence of genomic DNA using appro-
priate PCR primers. PCR reactions (20 Wl) were set up using Platinum
Taq DNA Polymerase (Life Technologies) and run on a GeneAmp
PCR System 9600 (Perkin Elmer, Rotkreuz, Switzerland). PCR con-
ditions were: 30 s denaturation at 94‡C, 45 s annealing at 60‡C and
1 min extension at 72‡C. For adipsin and PPARQ 26 PCR cycles were
carried out and for clathrin 30 cycles were run. The following primer
pairs were used (forward/reverse):
PPARQ : 5P aaactctgggagattctcct 3P/5P tcttgtgaatggaatgtctt 3P ;
Adipsin: 5P ctgctggacgagcagtgg 3P/5P gatgacactcgggtat 3P ;
Clathrin: 5P gacagtgccatcatgaatcc 3P/5P tttgtgcttctggaggaaagaa 3P
3. Results
The murine mesenchymal precursor cell line 3T3-L1 can be
e⁄ciently stimulated to undergo adipogenic di¡erentiation us-
ing a combination of thiazolidinediones and the phosphodies-
terase inhibitor IBMX [21]. We initially observed that high
concentrations of BMP-2 failed to inhibit adipogenesis under
these conditions, also when other cell systems were used. A
more careful analysis unexpectedly demonstrated a strong
synergy between BMP-2 and BRL 49653 in such di¡erentia-
tion assays. Fig. 1 shows a representative experiment of three
independent experiments carried out. Treatment of con£uent
3T3-L1 cell cultures for 14 days with either BMP-2 (500 ng/
ml) or BRL 49653 (1 WM) alone led only to a weak increase in
the number of adipocytes as assessed by Nile Red £ow cyto-
metry or Oil Red O staining (Fig. 1). However, combining
BMP-2 and thiazolidinedione resulted in strong adipogenic
di¡erentiation, comparable to the e¡ects of the standard adi-
pogenic treatment BRL 49653+IBMX (0.1 mM).
An almost identical picture emerged when GPDH activity,
a late adipocyte di¡erentiation marker, was measured bio-
chemically. GPDH activity was undetectable or weak in con-
trol cells or cells treated with BMP-2 or BRL 49653 alone,
respectively (Fig. 2, top). However, treatment with both
Table 1
Induction of adipogenesis in rat bone marrow mesenchymal cells by BMP-2, BRL 49653/IBMX and combinations
Treatment Experiment 1 Experiment 2
cyto£uorometry (% cells in R2) GPDH activity (mU/mg protein) GPDH activity (mU/mg protein)
Control 0.05 6 1 6 1
BMP-2 (500 ng/ml) 0.95 6 1 6 1
BRP 49653 (1 WM)+IBMX (200 WM) 7.4 5.62 5.81 þ 0.16
BMP-2+BRL+IBMX 14.0 26.02 1372(**) þ 0.80
Results of £ow cytometric analysis and GPDH activity measurements from two independent experiments. Cells were treated for 11 days. Aster-
isks indicate statistical signi¢cance (P6 0.01) compared to the treatment with BRL 49653/IBMX alone.
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agents together resulted in a strong synergistic response,
which was clearly signi¢cant (P6 0.015) in four of four inde-
pendent experiments. A concentration^response curve for
BMP-2 applied in the presence of BRL 49653 (1 WM) is shown
in Fig. 2, bottom. The protein stimulated GPDH activity with
an EC50 of approximately 200 ng/ml, which is in good agree-
ment with published data [22] and own experimental results
for osteogenic di¡erentiation of preosteoblasts (not shown).
We further assessed expression of the adipocyte markers
PPARQ and adipsin by RT-PCR under the experimental con-
ditions described above. Two independent sets of RNA were
prepared that gave identical results. Both PPARQ and adipsin
were detectable following a 10 day treatment with the thiazo-
lidinedione alone, whereas the corresponding bands could not
be detected in control cells or cells treated with BMP-2 (Fig.
3). Again, there was a substantial increase in the expression of
both PPARQ and adipsin visible following a combined treat-
ment with both agents.
In order to demonstrate the relevance of our ¢ndings for
cell systems other than 3T3-L1 we used primary mesenchymal
precursor cells isolated from rat bone marrow. As is shown in
Table 1, combined treatment with IBMX, BMP-2 and BRL
49653 resulted in a signi¢cant synergistic response in adipo-
cyte di¡erentiation, measured by £ow cytometry and the
GPDH activity of cultures.
4. Discussion
Adipogenesis is regulated by cell density and by growth and
di¡erentiation factors [23]. The nuclear hormone receptor
PPARQ is required for this process [6,7]. However, in most
experimental systems PPARQ activators alone are not su⁄-
cient to stimulate di¡erentiation signi¢cantly, but need to be
associated with glucocorticoids, insulin and/or cAMP-elevat-
ing agents like IBMX [7,9,13,21,24]. The precise interplay of
these factors inducing the adipogenic program is not fully
understood.
We show here that BMP-2 strongly stimulates adipogenesis
in vitro when associated with the thiazolidinedione BRL
49653. These results came unexpected as, based on earlier
studies, we had rather anticipated a pro-osteogenic and anti-
adipogenic e¡ect of this molecule [12^16]. We believe that our
results provide a rationale to explain diverging experimental
data obtained in the past with BMPs [12^17], as described in
Section 1. In fact, the adipogenic e¡ects observed with BMPs
likely depend on the expression and activity state of PPARQ in
a given cell type, which in turn can be modulated by culture
conditions and autocrine production of lipophilic messengers
that may act as PPARQ agonists [8,10].
Our results may also have important implications for our
understanding of osteoporosis, which is associated with the
Fig. 1. Induction of adipogenesis in 3T3-L1 cell cultures by BMP-2, BRL 49653, IBMX and combinations of these (14 days of treatment). Re-
sults of £ow cytometric analysis and Oil Red O staining of cultures. Bar: 50 Wm.
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unwanted adipogenic di¡erentiation of precursor cells in
bone marrow [12,25,26], where BMPs are known to be pro-
duced. The signalling status of PPARQ may in£uence BMP
action signi¢cantly in this biological context. It is conceivable
that antagonists or partial agonists of PPARQ [27,28] may
have bene¢cial e¡ects in osteoporosis, provided a potential
induction of insulin resistance would not occur [24].
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Fig. 2. Induction of GPDH activity in 3T3-L1 cell cultures. Top:
cells were treated for 14 days in the absence (ctrl) or presence of
BMP-2 (500 ng/ml), BRL 49653 (1 WM) and IBMX (100 WM). Bot-
tom: concentration^response curve for BMP-2 measured in the ab-
sence (ctrl) or presence of 0.1 WM of BRL 49653 after 14 days of
treatment. Asterisks indicate statistical signi¢cance compared to the
corresponding experimental condition not treated with BMP-2
(**P6 0.015; *P6 0.05).
Fig. 3. Expression of markers of adipogenic di¡erentiation (PPARQ,
adipsin) as assessed by RT-PCR. RNA was extracted from cells
after 10 days of treatment with BMP-2 (500 ng/ml), BRL 49653 (1
WM), IBMX (100 WM) and indicated combinations. Clathrin was
used as a control of cDNA quality.
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